Gilead Sciences, Inc. $GILD Position Cut by Zions Bancorporation National Association UT

by · The Markets Daily

Zions Bancorporation National Association UT trimmed its holdings in Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 13.3% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 34,838 shares of the biopharmaceutical company’s stock after selling 5,334 shares during the quarter. Zions Bancorporation National Association UT’s holdings in Gilead Sciences were worth $4,276,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Paulson Wealth Management Inc. boosted its stake in Gilead Sciences by 1.8% during the 4th quarter. Paulson Wealth Management Inc. now owns 3,887 shares of the biopharmaceutical company’s stock valued at $477,000 after purchasing an additional 67 shares in the last quarter. Essex Financial Services Inc. boosted its stake in Gilead Sciences by 0.9% during the 4th quarter. Essex Financial Services Inc. now owns 7,724 shares of the biopharmaceutical company’s stock valued at $948,000 after purchasing an additional 71 shares in the last quarter. Alpha Cubed Investments LLC boosted its stake in Gilead Sciences by 1.1% during the 4th quarter. Alpha Cubed Investments LLC now owns 6,619 shares of the biopharmaceutical company’s stock valued at $812,000 after purchasing an additional 75 shares in the last quarter. Personal CFO Solutions LLC boosted its stake in Gilead Sciences by 1.7% during the 4th quarter. Personal CFO Solutions LLC now owns 4,572 shares of the biopharmaceutical company’s stock valued at $561,000 after purchasing an additional 76 shares in the last quarter. Finally, Moss Adams Wealth Advisors LLC boosted its stake in Gilead Sciences by 1.7% during the 4th quarter. Moss Adams Wealth Advisors LLC now owns 4,446 shares of the biopharmaceutical company’s stock valued at $546,000 after purchasing an additional 76 shares in the last quarter. 83.67% of the stock is owned by institutional investors.

Gilead Sciences Stock Performance

Shares of Gilead Sciences stock opened at $121.48 on Thursday. The stock has a market cap of $150.83 billion, a PE ratio of 16.55 and a beta of 0.31. The business has a fifty day simple moving average of $133.73 and a 200-day simple moving average of $134.34. The company has a quick ratio of 1.77, a current ratio of 1.97 and a debt-to-equity ratio of 0.89. Gilead Sciences, Inc. has a 12 month low of $104.46 and a 12 month high of $157.29.

Gilead Sciences (NASDAQ:GILD – Get Free Report) last issued its earnings results on Thursday, May 7th. The biopharmaceutical company reported $2.03 EPS for the quarter, topping the consensus estimate of $1.91 by $0.12. The business had revenue of $6.96 billion during the quarter, compared to analysts’ expectations of $6.91 billion. Gilead Sciences had a return on equity of 48.19% and a net margin of 30.99%.Gilead Sciences’s revenue was up 4.4% compared to the same quarter last year. During the same quarter last year, the firm posted $1.81 earnings per share. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. On average, sell-side analysts anticipate that Gilead Sciences, Inc. will post -0.79 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, June 29th. Stockholders of record on Monday, June 15th will be given a $0.82 dividend. This represents a $3.28 annualized dividend and a dividend yield of 2.7%. The ex-dividend date of this dividend is Monday, June 15th. Gilead Sciences’s dividend payout ratio (DPR) is 44.69%.

Insider Transactions at Gilead Sciences

In other news, insider Johanna Mercier sold 28,000 shares of the firm’s stock in a transaction on Friday, May 15th. The stock was sold at an average price of $131.29, for a total value of $3,676,120.00. Following the completion of the sale, the insider owned 125,779 shares of the company’s stock, valued at $16,513,524.91. This trade represents a 18.21% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew D. Dickinson sold 3,000 shares of the firm’s stock in a transaction on Friday, May 15th. The stock was sold at an average price of $132.27, for a total value of $396,810.00. Following the completion of the sale, the chief financial officer directly owned 173,191 shares of the company’s stock, valued at approximately $22,907,973.57. This trade represents a 1.70% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 68,000 shares of company stock valued at $9,047,570 over the last quarter. Company insiders own 0.30% of the company’s stock.

Key Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

  • Positive Sentiment: Gilead and Merck reported positive Phase 3 results for a once-weekly HIV regimen using islatravir and lenacapavir, a potential advance that could strengthen Gilead’s already important HIV franchise and support long-term revenue growth. Article Title
  • Positive Sentiment: Analysts and recent commentary pointed to momentum in Gilead’s HIV portfolio, including strength in Biktarvy and Descovy, as well as improving expectations for Yeztugo and other late-stage pipeline assets. Article Title
  • Positive Sentiment: Gilead said topline Phase 3 IDEAL study results for Livdelzi in primary biliary cholangitis showed significantly more patients reached key treatment goals, which could broaden the company’s pipeline and add another growth driver. Article Title
  • Neutral Sentiment: Gilead presented at the Goldman Sachs Global Healthcare Conference, which likely reinforced management’s pipeline and growth narrative but did not appear to include a major new catalyst. Article Title
  • Negative Sentiment: Gilead and Merck also ended a Phase 3 lung cancer study after Trodelvy plus KEYTRUDA failed to deliver a statistically significant improvement, renewing concern around Gilead’s oncology strategy. Article Title
  • Negative Sentiment: Biopharma coverage noted that the Trodelvy setback creates risk for one of Gilead’s key cancer programs, even as HIV progress remains the bigger driver for the stock. Article Title

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on the company. Daiwa Securities Group decreased their price target on Gilead Sciences from $161.00 to $150.00 and set an “outperform” rating for the company in a research note on Tuesday, May 19th. Jefferies Financial Group assumed coverage on Gilead Sciences in a research note on Tuesday, March 10th. They set a “buy” rating and a $180.00 price target for the company. Scotiabank increased their price target on Gilead Sciences from $140.00 to $177.00 and gave the company a “sector outperform” rating in a research note on Wednesday, February 11th. Royal Bank Of Canada reaffirmed a “sector perform” rating on shares of Gilead Sciences in a research note on Monday. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $170.00 price target on shares of Gilead Sciences in a research note on Monday, February 23rd. Twenty-five investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $156.93.

Read Our Latest Research Report on GILD

Gilead Sciences Profile

(Free Report)

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.

See Also